These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 22958421)

  • 21. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD009528. PubMed ID: 28981972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009528. PubMed ID: 25741986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of oxygen limitation on the in vitro antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa grown planktonically and as biofilms.
    Field TR; White A; Elborn JS; Tunney MM
    Eur J Clin Microbiol Infect Dis; 2005 Oct; 24(10):677-87. PubMed ID: 16249934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phenotypic and Genotypic Adaptations in Pseudomonas aeruginosa Biofilms following Long-Term Exposure to an Alginate Oligomer Therapy.
    Oakley JL; Weiser R; Powell LC; Forton J; Mahenthiralingam E; Rye PD; Hill KE; Thomas DW; Pritchard MF
    mSphere; 2021 Jan; 6(1):. PubMed ID: 33472983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-Dose Nitric Oxide as Targeted Anti-biofilm Adjunctive Therapy to Treat Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis.
    Howlin RP; Cathie K; Hall-Stoodley L; Cornelius V; Duignan C; Allan RN; Fernandez BO; Barraud N; Bruce KD; Jefferies J; Kelso M; Kjelleberg S; Rice SA; Rogers GB; Pink S; Smith C; Sukhtankar PS; Salib R; Legg J; Carroll M; Daniels T; Feelisch M; Stoodley P; Clarke SC; Connett G; Faust SN; Webb JS
    Mol Ther; 2017 Sep; 25(9):2104-2116. PubMed ID: 28750737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.
    Hill D; Rose B; Pajkos A; Robinson M; Bye P; Bell S; Elkins M; Thompson B; Macleod C; Aaron SD; Harbour C
    J Clin Microbiol; 2005 Oct; 43(10):5085-90. PubMed ID: 16207967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic effects of pomegranate and rosemary extracts in combination with antibiotics against antibiotic resistance and biofilm formation of Pseudomonas aeruginosa.
    Abu El-Wafa WM; Ahmed RH; Ramadan MA
    Braz J Microbiol; 2020 Sep; 51(3):1079-1092. PubMed ID: 32394240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009528. PubMed ID: 23152277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The ionophore oxyclozanide enhances tobramycin killing of Pseudomonas aeruginosa biofilms by permeabilizing cells and depolarizing the membrane potential.
    Maiden MM; Zachos MP; Waters CM
    J Antimicrob Chemother; 2019 Apr; 74(4):894-906. PubMed ID: 30624737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phenotypic shift in Pseudomonas aeruginosa populations from cystic fibrosis lungs after 2-week antipseudomonal treatment.
    Fernández-Barat L; Ciofu O; Kragh KN; Pressler T; Johansen U; Motos A; Torres A; Hoiby N
    J Cyst Fibros; 2017 Mar; 16(2):222-229. PubMed ID: 27651273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers Retain Activity against Multidrug-Resistant Pseudomonas aeruginosa
    Moustafa DA; Wu AW; Zamora D; Daly SM; Sturge CR; Pybus C; Geller BL; Goldberg JB; Greenberg DE
    mBio; 2021 Jan; 12(1):. PubMed ID: 33436433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential novel therapeutic strategies in cystic fibrosis: antimicrobial and anti-biofilm activity of natural and designed α-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia.
    Pompilio A; Crocetta V; Scocchi M; Pomponio S; Di Vincenzo V; Mardirossian M; Gherardi G; Fiscarelli E; Dicuonzo G; Gennaro R; Di Bonaventura G
    BMC Microbiol; 2012 Jul; 12():145. PubMed ID: 22823964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination antibiotic susceptibility of biofilm-grown Burkholderia cepacia and Pseudomonas aeruginosa isolated from patients with pulmonary exacerbations of cystic fibrosis.
    Dales L; Ferris W; Vandemheen K; Aaron SD
    Eur J Clin Microbiol Infect Dis; 2009 Oct; 28(10):1275-9. PubMed ID: 19575248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cephalosporin nitric oxide-donor prodrug DEA-C3D disperses biofilms formed by clinical cystic fibrosis isolates of Pseudomonas aeruginosa.
    Soren O; Rineh A; Silva DG; Cai Y; Howlin RP; Allan RN; Feelisch M; Davies JC; Connett GJ; Faust SN; Kelso MJ; Webb JS
    J Antimicrob Chemother; 2020 Jan; 75(1):117-125. PubMed ID: 31682251
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single and combination antibiotic susceptibilities of planktonic, adherent, and biofilm-grown Pseudomonas aeruginosa isolates cultured from sputa of adults with cystic fibrosis.
    Aaron SD; Ferris W; Ramotar K; Vandemheen K; Chan F; Saginur R
    J Clin Microbiol; 2002 Nov; 40(11):4172-9. PubMed ID: 12409393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of colistin against biofilm by Pseudomonas aeruginosa is significantly improved under "cystic fibrosis-like" physicochemical conditions.
    Pompilio A; Crocetta V; Pomponio S; Fiscarelli E; Di Bonaventura G
    Diagn Microbiol Infect Dis; 2015 Aug; 82(4):318-25. PubMed ID: 26004353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre.
    Manno G; Cruciani M; Romano L; Scapolan S; Mentasti M; Lorini R; Minicucci L
    Int J Antimicrob Agents; 2005 Mar; 25(3):193-7. PubMed ID: 15737511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of antimicrobial resistance, biofilm forming potential, and the presence of biofilm-related genes among clinical isolates of Pseudomonas aeruginosa.
    Kamali E; Jamali A; Ardebili A; Ezadi F; Mohebbi A
    BMC Res Notes; 2020 Jan; 13(1):27. PubMed ID: 31924268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stationary biofilm growth normalizes mutation frequencies and mutant prevention concentrations in Pseudomonas aeruginosa from cystic fibrosis patients.
    García-Castillo M; del Campo R; Baquero F; Morosini MI; Turrientes MC; Zamora J; Cantón R
    Clin Microbiol Infect; 2011 May; 17(5):704-11. PubMed ID: 20673272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection.
    Hengzhuang W; Wu H; Ciofu O; Song Z; Høiby N
    Antimicrob Agents Chemother; 2012 May; 56(5):2683-90. PubMed ID: 22354300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.